Matrix Metalloproteinases in Acute Intracerebral Hemorrhage.
Simona LattanziMario Di NapoliSilvia RicciAfshin A DivaniPublished in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2021)
Spontaneous intracerebral hemorrhage (ICH) accounts for 10-30% of all strokes and affects more than one million people every year worldwide, and it is the stroke subtype associated with the highest rates of mortality and residual disability. So far, clinical trials have mainly targeted primary cerebral injury and have substantially failed to improve clinical outcomes. The understanding of the pathophysiology of early and delayed injury after ICH is, hence, of paramount importance to identify potential targets of intervention and develop effective therapeutic strategies. Matrix metalloproteinases (MMPs) represent a ubiquitous superfamily of structurally related zinc-dependent endopeptidases able to degrade any component of the extracellular matrix. They are upregulated after ICH, in which different cell types, including leukocytes, activated microglia, neurons, and endothelial cells, are involved in their synthesis and secretion. The aim of this review is to summarize the available experimental and clinical evidence about the role of MMPs in brain injury following spontaneous ICH and provide critical insights into the underlying mechanisms.
Keyphrases
- brain injury
- subarachnoid hemorrhage
- extracellular matrix
- cerebral ischemia
- clinical trial
- endothelial cells
- randomized controlled trial
- liver failure
- multiple sclerosis
- single cell
- atrial fibrillation
- spinal cord
- inflammatory response
- respiratory failure
- drug induced
- cell therapy
- neuropathic pain
- stem cells
- peripheral blood
- human health
- open label
- risk assessment
- high glucose
- mesenchymal stem cells
- transcription factor
- vascular endothelial growth factor
- phase iii
- aortic dissection
- hepatitis b virus